Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
The study will be published on the pre-print server, medRXiv, shortly
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
The drug is priced at Rs 2000 for a course of 40 tablets
The brand is now available pan-India through their distribution partner
It is the generic version of molnupiravir
Subscribe To Our Newsletter & Stay Updated
